Influence of Habitual Protein Intake on AA Tracer Oxidation
NCT ID: NCT03845569
Last Updated: 2019-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2017-11-01
2018-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validating IAAO for Muscle Outcomes
NCT07317921
Protein Requirements in Resistance-trained Males
NCT03696264
Protein Requirements in Resistance Trained Females
NCT03397043
The Impact of Protein Intake on Protein Metabolism During Intensified Training
NCT02801344
Measuring Protein Requirement Using Amino Acid Oxidation in Strength and Endurance Athletes
NCT02621294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
High Protein Phase The high protein phase is three days in length, with diet-controlled throughout, and a metabolic trail on day 3. Participants will perform whole-body resistance exercise on days one and three.
Moderate protein phase The Moderate protein phase is seven days in length, with MT on days three, five and seven. Dietary intake will be controlled throughout the whole phase providing either 2.2 g/kg/d of protein (days one and two), or 1.2 g/kg/d (days three through seven). Full body resistance exercise will be performed performed on days one, three, five and seven.
This phase will allow measurement of protein metabolism over five days following a decrease in dietary protein intake, and to determine the effect of dietary changes on the IAAO method.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Habitual Protein phase
A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
Three day Controlled Diet
Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
Moderate Protein Phase
A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
Dietary protein intake reduction
Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary protein intake reduction
Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
Three day Controlled Diet
Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Habitually dietary protein consumption of 1.9 to 3.0g/kg/d
* Train each muscle group (i.e. chest, back, legs) at least twice a week
* Body mass stable in the last month
* Meets strength relative-to-weight guidelines (adapted from Morton et al., 2016; Chilibeck et -al., 1997)
* Bench Press: - Bodyweight (kg) \* 1.25
* Leg Press: - Bodyweight (kg) \*4.0
Exclusion Criteria
* Inability to adhere to any of the protocol guidelines (e.g. alcohol and caffeine consumption)
* Regular tobacco use, screened by questionnaire
* Illicit drug use (e.g. growth hormone, testosterone, etc.), screened by a survey in training log
* 1 month sedentary in the last 6 months prior to study participation
* 30 minutes of continuous cardio per exercise session
* BMI \> or equal to 35
* Individual plans to increase or decrease body mass in the next 3 months
* Use of supplements (excluding whey protein), such as creatine and beta-alanine, in the last 30 days
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Moore
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel R Moore, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Goldring Centre for High Performance Sport
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tinline-Goodfellow CT, West DWD, Malowany JM, Gillen JB, Moore DR. An Acute Reduction in Habitual Protein Intake Attenuates Post Exercise Anabolism and May Bias Oxidation-Derived Protein Requirements in Resistance Trained Men. Front Nutr. 2020 Apr 22;7:55. doi: 10.3389/fnut.2020.00055. eCollection 2020.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HPI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.